Today: 4 July 2026
Browse Category

SGX:Y92 12 December 2025 - 1 February 2026

Singapore’s stock revival lifts IPO fundraising — and dividend hunters are chasing ThaiBev

Singapore’s stock revival lifts IPO fundraising — and dividend hunters are chasing ThaiBev

Singapore’s stock market revival in 2025 is drawing new listings and fresh interest in dividend plays, as policymakers and the Singapore Exchange try to turn a rally into lasting liquidity. CNA+1 The push matters because Singapore has spent years battling thin trading and a shortage of big initial public offerings, or IPOs — the first sale of shares to the public — problems that can depress valuations and drive companies to list elsewhere. CNA
29 December 2025
··
Thai Beverage (SGX: Y92) Stock: Latest News, FY2025 Earnings, Dividend Outlook, and Analyst Forecasts (Dec 12, 2025)

Thai Beverage (SGX: Y92) Stock: Latest News, FY2025 Earnings, Dividend Outlook, and Analyst Forecasts (Dec 12, 2025)

Updated: Friday, December 12, 2025 — Thai Beverage Public Company Limited shares are trading in a tight range in early December as investors digest FY2025 results, a confirmed full-year dividend, and a wave of broker note adjustments that mostly keep a constructive medium-term view—while acknowledging softer near-term consumption and cost pressures. As of December 12, 2025, ThaiBev is trading around S$0.465–S$0.470, with a 52-week range of about S$0.435 to S$0.575. Investing.com+1
12 December 2025
·

Stock Market Today

  • Mettler-Toledo (MTD) Revenue Beats in Mixed Quarter, Research Tools Stocks Up 20% Since Q1
    July 4, 2026, 1:27 AM EDT. The Research Tools & Consumables group reported Q1 revenue up 1.3% over analyst estimates, serving customers in academia, biotech, and pharma. Mettler-Toledo (NYSE:MTD) booked $947.1 million in sales, up 7.2% from last year and just ahead of forecasts. EPS was less clear, and the stock hovered around $1,308 after the update. Sector shares, on average, climbed 20.8% post-earnings as demand stayed hot for lab tools tied to synthetic biology and personalized medicine. Patchy research funding and supply chain hiccups remain risks. Waters Corporation (NYSE:WAT) was the top mover, with strong Q1 gains from its analytical instruments and consumables business.
Go toTop